Trial Profile
Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients With Melanoma or Non-Small Cell Lung Cancer (NSCLC) Brain Metastases (BM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions
- 02 Nov 2022 Planned End Date changed from 1 Oct 2022 to 28 Oct 2023.
- 14 Oct 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 14 Oct 2021 Status changed from recruiting to active, no longer recruiting.